About AWAKN
AWAKN is a company based in Portishead (United Kingdom) founded in 2020 was acquired by Solvonis Therapeutics in February 2025. The company has 49 employees as of May 27, 2025. AWAKN has completed 2 acquisitions, including AXON Klinikken and Dr Ben Sessa. AWAKN offers products and services including AWKN-001, AWKN-002, and AWKN-SDN-14. AWAKN operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
- Headquarter Portishead, United Kingdom
- Employees 49 as on 27 May, 2025
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Awakn Life Sciences Uk Ltd
- Date of Incorporation 24 Jul, 2020
- Jurisdiction LONDON
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$141.05 K (USD), Post-IPO
Mar 06, 2025
- Investors
-
Employee Count
49
as on May 27, 2025
-
Investments & Acquisitions
AXON Klinikken
& 1 more
-
Acquired by
Solvonis Therapeutics
(Feb 24, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AWAKN
AWAKN offers a comprehensive portfolio of products and services, including AWKN-001, AWKN-002, and AWKN-SDN-14.
Medication for treating Alcohol Use Disorder.
Treatment targeting substance use disorders.
Therapeutic for mental health and addiction issues.
People of AWAKN
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of AWAKN
Investors in AWAKN
AWAKN has secured backing from 1 investor. Prominent investors backing the company include Solvonis Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Novel therapeutics for addiction and mental health disorders are developed.
|
Locked | Locked | Locked |
Investor details for AWAKN
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AWAKN
AWAKN has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include AXON Klinikken and Dr Ben Sessa.
Investment portfolio details for AWAKN
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Standalone mental clinic
|
Locked | Locked | 2018 | Locked | |
|
Provider of psychiatric consultation services
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for AWAKN
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - AWAKN
Detailed financials for AWAKN
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Awakn Comparisons
Peer comparison for AWAKN
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AWAKN
AWAKN operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of neurological and psychiatric disorders
|
|
| Locked | Locked | Locked |
Psychedelic therapeutics for psychiatric disorders are developed and provided.
|
|
| Locked | Locked | Locked |
Psychedelic-derived therapeutics for mental illnesses are developed.
|
Detailed competitors of AWAKN
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Awakn
Complete news archive for AWAKN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AWAKN
AWAKN was founded in 2020 and raised its 1st funding round 2 years after it was founded.
AWAKN is headquartered in Portishead, United Kingdom. It is registered at Portishead, England, United Kingdom.
As of May 27, 2025, the latest employee count at AWAKN is 49.
AWAKN was established in 2020 and is headquartered in Portishead, United Kingdom. Operations as a contract research organization (CRO) in the life sciences sector are centered on early-stage clinical trials. Research services for drug development and clinical studies are offered, with emphasis on trial design, execution, and data management. Geographic focus remains within the UK, supporting pharmaceutical and biotech clients in regulatory-compliant research processes.
AWAKN's top competitors include MindMed, COMPASS Pathways and Beckley Psytech.
AWAKN offers AWKN-001, AWKN-002, and AWKN-SDN-14.
AWAKN has made 2 acquisitions, including AXON Klinikken, and Dr Ben Sessa.
AWAKN has 1 investor. Key investors include Solvonis Therapeutics.